The Impact of Radiotherapy on Oligometastatic Cancer
Stereotactic ABlative Radiotherapy (SABR) in Oligometastatic Cancer (OC): a Radiomics, Multi-omics, and Machine Learning Approach to Clinical Decision-making. the OC-SABR Multicentric Project
Institut Investigacio Sanitaria Pere Virgili
2,000 participants
Dec 1, 2022
OBSERVATIONAL
Conditions
Summary
Metastases represent the most threatening challenge in cancer. One of the management strategies for patients with Oligometastatic Cancer (OC) is Stereotactic ABlative Radiotherapy (SABR). However, there are few studies, and there is no defined clinical standard, nor are the radiobiological mechanisms that contribute to treatment response well understood. The focus should be on generating evidence to guide the personalization of radiotherapy beyond solely technological and anatomical precision. This could be achieved by recollecting clinical and biological data from patients that undergo this treatment and analyzing them to ultimately predict, with the help of artificial intelligence, which patients will be the most beneficiary and improve their survival rate.
Eligibility
Inclusion Criteria4
- Histologic confirmation of primary tumor: breast, prostate, lung, colorectal.
- years old or older.
- Up to five metastases located in the bone, lung, node, liver or brain.
- Eastern Cooperative Oncology Group (ECOG) Performance Status Scale 0 or 1.
Exclusion Criteria4
- Non-melanoma skin cancer.
- Previous radiotherapy in the same anatomic location.
- Presence of vascular collagen disease.
- Pregnancy or lactation at the time of inclusion.
Interventions
Analyze clinical data, medical images and molecular circulating features to propose which variables serve to select the patients that will achieve complete response after SABR.
Collect blood samples at five different time points before and after treatment and analyze circulating tumoral DNA, medical images, and metabolites to monitor the effect of SABR and its effectiveness.
Analyze circulating tumoral DNA and metabolites from blood samples in search of the profile of OC.
Locations(21)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05933876